Alpivab (peramivir)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- peramivir
- Company
- Biocryst
- Status
- Withdrawn
- Therapeutic area
- Influenza, Human
- EU approval
- Fri 13 Apr 2018
- Designations
- Additional monitoring
- Application
- EMEA/H/C/004299
- ATC
- J05AH03
- Official record
- www.ema.europa.eu
Indication
Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years.
Regulatory milestones
No milestones recorded in the last year.
Follow Alpivab
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.